Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as combined diagnosis marker in lung cancer diagnosis

A diagnostic marker and technology for lung cancer, applied in the field of medical diagnosis, can solve problems such as the complexity of performance, and achieve the effects of improving sensitivity, increasing 5-year survival rate, and improving screening quality

Active Publication Date: 2020-06-23
FUJIAN PROVINCIAL HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above studies have shown that the abnormally high expression of TIF1γ may be involved in the occurrence and development of intestinal cancer and breast cancer, but it has been reported in the literature that the expression of TIF1γ is significantly down-regulated in monocytes and pancreatic cancer [Aucagne R, Droin N, Paggetti J, et al.Transcription intermediary factor1gamma is a tumor suppressor in mouse and human chronic myelomonocyticleukemia. J Clin Invest.2011; 121(6):2361-2370.], [Vincent DF, Gout J, Chuvin N, et al. Tif1gamma suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway.Am JPathol.2012;180(6):2214-2221.], suggesting that TIF1γ may participate in different tumorigenesis and development processes in different ways, with complex manifestations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as combined diagnosis marker in lung cancer diagnosis
  • Application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as combined diagnosis marker in lung cancer diagnosis
  • Application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as combined diagnosis marker in lung cancer diagnosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] 1 Materials and methods

[0019] 1.1 Research object

[0020] 248 patients with early lung cancer, 200 patients with benign lung lesions (LBL), and 218 healthy controls (HC), all from Fujian Provincial Hospital from September 2016 to October 2018. All patients strictly met the diagnostic criteria recognized by international or professional societies, and had not received any form of anti-tumor therapy before. The clinical and pathological data of the patients are shown in Table 1. HC is a healthy person from the physical examination center of Fujian Provincial Hospital, and excludes malignant tumors in the lung and other parts, as well as non-malignant lung lesions such as pneumonia and lung abscess. All research subjects collected 5ml of fasting peripheral venous blood before operation, centrifuged at 3000rpm at 4°C for 10min, collected serum, and stored it at -80°C for later use; randomly selected 60 cases of cancer tissues and paired paracancerous tissues from 248 c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of anti-TIF1 gamma-IgA and anti-TIF1 gamma-IgG as a combined diagnosis marker in early diagnosis of a lung cancer, and belongs to the technical field of medical diagnosis. A condition thata TIF1 gamma protein is abnormally highly expressed in cancer tissues of a patient with an early lung cancer is found for the first time; meanwhile, a strong humoral immune response aiming at TIF1gamma is found to exist in a body of the patient at the early stage of the lung cancer; serum anti-TIF1 gamma-IgA and TIF1 gamma-IgG autoantibodies can be used as markers for early diagnosis of the lung cancer; and combined detection of the anti-TIF1 gamma-IgA and the anti-TIF1 gamma-IgG can obviously improve sensitivity of the early diagnosis of the lung cancer patient on the basis of ensuring specificity, and the application is suitable for being developed into a combined detection kit with a clinical application value. Therefore, the combined detection of the anti-TIF1gamma-IgA and the anti-TIF1 gamma-IgG is helpful for further improving early serological screening quality of the lung cancer patient so that a cure rate and a five-year survival rate of the lung cancer are increased.

Description

technical field [0001] The invention belongs to the technical field of medical diagnosis, and specifically relates to the application of anti-TIF1γ-IgA and anti-TIF1γ-IgG as combined diagnostic markers in the early diagnosis of lung cancer. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality rate in the world today, and it is a serious hazard to human health. Early diagnosis and timely surgical radical resection are of great significance to the prognosis of lung cancer patients. Studies have shown that the 5-year survival rate of lung cancer patients undergoing surgery at stage I can be as high as 92% [Goldstraw P, Chansky K, Crowley J, et al. The IASLCLung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. JThorac Oncol. 2016; 11(1): 39-51.]; It is found that most patients are already in the advanced stage of the disease ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574
CPCG01N33/57423G01N33/57488
Inventor 黄毅余丽丽吴庆伟林晓青章良铭张松高
Owner FUJIAN PROVINCIAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com